The earnings call reflected a positive trajectory for Teva Pharmaceuticals, highlighted by continued growth in its innovative brands and a strategic focus on biosimilar launches and cost savings to drive future growth. Despite challenges in the generic segment and uncertainties related to tariffs and specific product headwinds, Teva remains confident in achieving its financial targets through focused capital allocation and operational efficiencies.

Company Guidance -

Q2 2025

In the Q1 2025 earnings call for Teva Pharmaceutical Industries Limited, leadership highlighted several key metrics that emphasize the company's growth trajectory and strategic focus. Revenue increased by 5% to $3.9 billion, marking the ninth consecutive quarter of growth. Adjusted EBITDA rose by 3%, while non-GAAP EPS reached $0.52, an 8% increase. The company's innovative brands, Austedo, Ajovy, and Uzedy, were strong contributors, with Austedo's sales growing 39% globally, Ajovy up 26%, and Uzedy sales doubling to $39 million. Additionally, Teva's generic business saw a 3% growth, and biosimilar launches are expected to further support revenue. The company is focused on achieving a 30% operating margin by 2027, with planned savings of $700 million from operational efficiencies, and aims for sustainable growth driven by its innovative portfolio and disciplined capital allocation.

Ninth Consecutive Quarter of Growth

Teva Pharmaceutical Industries has achieved its ninth consecutive quarter of growth, with revenue up 5% to $3.9 billion.

Strong Performance of Innovative Brands

Innovative brands reached $589 million in sales, a 45% increase over last year. Austedo grew 39%, Ajovy increased by 26%, and Uzedy's sales doubled.

Positive Outlook and Biosimilar Launches

Teva plans to launch five new biosimilar products from 2025 to 2027, with potential for some to launch in 2025, further supporting growth.

Improved Financial Metrics

Non-GAAP EPS increased by 8% to $0.52, and the adjusted EBITDA grew by 3%. Gross margin improved by 140 basis points year-over-year to 52.8%.

Debt Reduction and Strong Cash Flow

Net debt reduced to $15 billion, with a net debt-to-EBITDA ratio just over three times. Free cash flow is strong, aligning with long-term goals.

Cost Savings and Margin Expansion Plan

Teva plans to achieve $700 million in net savings by 2027, improving operating margins to 30% by 2027.

Teva Pharmaceutical (TEVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TEVA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2025	2025 (Q2)	0.64 / -	0.61	―	―	―
May 07, 2025	2025 (Q1)	0.46 / 0.52	0.48	8.33% (+0.04)
Jan 29, 2025	2024 (Q4)	0.71 / 0.71	1	-29.00% (-0.29)
Nov 06, 2024	2024 (Q3)	0.66 / 0.69	0.6	15.00% (+0.09)
Jul 31, 2024	2024 (Q2)	0.55 / 0.61	0.56	8.93% (+0.05)
May 08, 2024	2024 (Q1)	0.51 / 0.48	0.4	20.00% (+0.08)
Jan 31, 2024	2023 (Q4)	0.77 / 1.00	0.71	40.85% (+0.29)
Nov 08, 2023	2023 (Q3)	0.61 / 0.60	0.59	1.69% (+0.01)
Aug 02, 2023	2023 (Q2)	0.53 / 0.56	0.68	-17.65% (-0.12)
May 10, 2023	2023 (Q1)	0.56 / 0.40	0.55	-27.27% (-0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TEVA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$16.12	$17.60	+9.18%
Jan 29, 2025	$21.53	$18.54	-13.89%
Nov 06, 2024	$18.77	$17.43	-7.14%
Jul 31, 2024	$16.41	$17.43	+6.22%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.